Author: Morens, David M.; Fauci, Anthony S.
Title: Emerging Infectious Diseases in 2012: 20 Years after the Institute of Medicine Report Document date: 2012_12_11
ID: u178w3kj_11
Snippet: Since 1992, high-throughput genetics techniques have led to the sequencing of thousands of microorganisms, their vectors, and many of their hosts. Genomics and proteomics have helped in the discovery of new infectious diseases and in acquiring a better understanding of the pathogenesis of existing ones; have substantially improved surveillance, diagnosis, and drug and vaccine design; and promise to help elucidate host susceptibility factors and h.....
Document: Since 1992, high-throughput genetics techniques have led to the sequencing of thousands of microorganisms, their vectors, and many of their hosts. Genomics and proteomics have helped in the discovery of new infectious diseases and in acquiring a better understanding of the pathogenesis of existing ones; have substantially improved surveillance, diagnosis, and drug and vaccine design; and promise to help elucidate host susceptibility factors and host responses to treatment of infections. For example, by 2003, the genomes of the human species, the mosquito Anopheles gambiae, and the malaria parasite Plasmodium falciparum all had been sequenced, representing the first time that all the major actors in the drama of an important emerging/reemerging infectious disease had been characterized at the molecular genetic level (12, 14) . These breakthroughs are important additions to our continuing efforts to control malaria, which have had recent successes but still require new countermeasures. These genomic data are contributing to vaccine and drug development and are elucidating the pathogenesis of and human resistance and susceptibility to malaria (14) .
Search related documents:
Co phrase search for related documents- Anopheles gambiae and drug development vaccine: 1
- Anopheles gambiae and high throughput: 1
- continue effort and high throughput: 1
- drug development and genetic level: 1, 2
- drug development and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- drug development and host response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- drug development and host susceptibility: 1, 2, 3, 4
- drug development vaccine and genetic level: 1
- drug development vaccine and high throughput: 1, 2, 3, 4, 5, 6
- drug development vaccine and host response: 1, 2, 3, 4
- drug development vaccine and host susceptibility: 1, 2
- exist one and high throughput: 1
- exist one and host response: 1
- genetic level and high throughput: 1, 2, 3
- genetic level and host response: 1, 2, 3, 4, 5
- genetic level and host susceptibility: 1, 2
- high throughput and host response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high throughput and host susceptibility: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date